AUTHORS
Andrew A. Lane, MD, PhD, Marina Konopleva, MD, PhD2, Kendra L. Sweet, MD, MS3, Anthony Selwyn Stein, MD4, David A. Rizzieri, MD5, Eunice Sue Wang, MD6, Sumithira Vasu, MBBS., MD7, Todd Rosenblat, MD8, Taha Al-Juhaishi, MD9, Dylan Barth, MD10, Alessandra Tosolini, MD, PhD11, Muzaffar Qazilbash, MD12, Naveen Pemmaraju, MD13
AFFILIATIONS
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Albert Einstein College of Medicine/Montefiore Cancer Center, Bronx, New York, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 City of Hope, Duarte, California, United States
5 Novant Health Cancer Institute, Charlotte, North Carolina, United States
6 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
7 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
8 Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York, United States
9 OU Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
10 Menarini Group, New York, New York, United States
11 Menarini Group, New York, New York, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background
TAG, a first-in-class CD123-targeted therapy comprising human interleukin-3 conjugated to a truncated diphtheria toxin (DT) payload, is the first approved treatment for BPDCN in the US and EU. The pivotal phase 2 trial enrolled 65 treatment-naïve pts. The overall response rate was 75%, including a complete response (CR)/clinical CR (CRc) rate of 57%; median time to response was 39 days; median duration of CR/CRc was 24.9 months (mo; Pemmaraju JCO 2022). TAG has a well-characterized and manageable safety profile, with transient adverse events (AEs) occurring mostly in cycle (C) 1, no cumulative toxicity or myelosuppression, with the majority of pts having restoration of normal hematopoiesis during treatment (Konopleva Cancer 2026). Any-grade alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations were reported in 64% and 60% of pts, respectively, in the pivotal trial, which were transient and mostly in C1. While the mechanism of TAG-associated hepatic abnormalities is unclear, hypotheses suggest it may be due to direct hepatic impact from DT administration or uptake of TAG-induced immune complexes formed from prior DT vaccinations (NIH LiverTox 2019). Here, we aimed to characterize TAG-associated hepatic abnormalities.
Methods
This descriptive subgroup analysis of the pivotal trial (NCT02113982) included treatment-naïve BPDCN pts from the safety population who received TAG 12 µg/kg. Pts were assigned groups based on development of treatment-emergent AE (TEAE) hepatic abnormalities (combined liver-related AE terms [ie, ALT/AST, alkaline phosphatase (AP), hyperbilirubinemia, hepatobiliary disorders, VOD]; referred to as HA-present) or not (HA-absent) during C1. The R-value (R=[ALT/ALT upper limit of normal (ULN)] ÷ [serum AP/AP ULN]) was calculated to classify hepatic changes in C1 as hepatocellular (R>5), mixed (R=2-5), or cholestatic (R<2; Chalasani ACG 2014).
Results
Sixty-six pts were included (HA-present, n=43; HA-absent, n=23). Median age was 65 vs 69 years in the HA-present vs HA-absent groups, respectively. Baseline skin disease was present in 91% vs 96% of pts, and ≥2 sites of disease were noted in 79% vs 48%. The most frequent TEAEs in HA-present and HA-absent pts were similar to those in the full pt population, including capillary leak syndrome (CLS; 19% vs 17%). Differences in grade (gr) 3-4 TEAEs between the 2 groups were primarily related to hepatic abnormalities and hematologic TEAEs.
In C1, 47% of hepatic abnormality TEAEs were gr 1-2, 53% were gr 3-4; no gr 5 events. The most common gr 3-4 hepatic TEAEs were ALT (44%) and AST (40%) elevations. Hyperbilirubinemia occurred in 2 pts (1 pt gr 3-4) and resolved. There were no cases of VOD in any treatment cycle. The median time to hepatic abnormality TEAE onset was 5 days with a 74% resolution rate and median time to resolution of 15 days; resolution rates for gr 3-4 TEAEs were 79% for ALT, 76% for AST, and 100% for hyperbilirubinemia. For pts with unresolved hepatic TEAEs, 2 bridged to stem cell transplantation (SCT), 3 discontinued due to AEs, 3 withdrew (1 physician and 2 pt choice), and 3 remained on treatment until progression.
The median R-value for HA-present pts with a hepatic abnormality TEAE at any time in C1 was 7.1, with a C1 day 8 median R-value of 5.6, coinciding with the onset of hepatic abnormalities and indicating a predominantly hepatocellular pattern rather than a cholestatic process. Subsequent R-values on days 15 and 21 demonstrated a declining pattern, aligning with the median duration and resolution of the hepatic abnormalities.
Efficacy outcomes were similar regardless of the development of hepatic abnormalities. Median overall survival was 18 mo in HA-present pts vs 15.8 mo in HA-absent pts, and bridge to SCT rates at any time were similar between groups (49% vs 48%). Only one pt (HA-present; gr 1 resolved in C1) who bridged to SCT immediately after TAG had post-SCT VOD.
Conclusions
TAG’s liver AE profile is a transient, manageable biochemical event characterized by C1 hepatic abnormalities with a 74% resolution rate and a median duration of 15 days. A median R-value >5 in C1 characterizes this profile as a hepatocellular pattern rather than a cholestatic process, with no reported cases of on-treatment VOD. Moreover, the development of hepatic abnormalities is not associated with increased CLS incidence and does not compromise long-term outcomes, as demonstrated by similar SCT rates (49% vs 48%).
DISCLOSURES
Andrew A. Lane, MD, PhD: Medzown - Current holder of stock options in a privately-held company; Stelexis BioSciences - Current holder of stock options in a privately-held company; Stemline Therapeutics - Research Funding; AbbVie - Research Funding; IDRx - Consultancy (Includes expert testimony); ProteinQure - Consultancy (Includes expert testimony); Cimeio Therapeutics - Consultancy (Includes expert testimony); Stemline Therapeutics - Consultancy (Includes expert testimony); Qiagen - Consultancy (Includes expert testimony); Jnana Therapeutics - Consultancy (Includes expert testimony); Stelexis BioSciences - Consultancy (Includes expert testimony)